Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzgalantamine - AlphaCognition

Next Previous
Drug Profile

Benzgalantamine - AlphaCognition

Alternative Names: Alpha 1062; ALPHA-1062 Intranasal; ALPHA-1062IN; Benzgalantamine Gluconate; Galantamine benzoate - AlphaCognition; Galantamine pro-drug - AlphaCognition; GLN-1062; Memogain; Pro-galantamine - AlphaCognition; ZUNVEYL

Latest Information Update: 23 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galantos Pharma
  • Developer AlphaCognition; China Medical System
  • Class Alkaloids; Antidementias; Benzazepines; Benzoates; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • Preclinical Traumatic brain injuries

Most Recent Events

  • 18 Feb 2026 Alpha Cognition has patent protection for benzgalantamine in USA
  • 07 Jan 2026 Alpha Cognition plans to submit IND for treatment of mild-to-moderate mild-to-moderate Alzheimer’s Disease
  • 13 Nov 2025 Benzgalantamine has boxed warning for patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL regarding serious skin reactions

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top